Compare SGRY & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SGRY | ARDX |
|---|---|---|
| Founded | 2004 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.6B |
| IPO Year | 2015 | 2014 |
| Metric | SGRY | ARDX |
|---|---|---|
| Price | $14.27 | $6.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 9 |
| Target Price | ★ $26.50 | $14.67 |
| AVG Volume (30 Days) | 1.9M | ★ 3.8M |
| Earning Date | 05-26-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 54.14 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,145,438,000.00 | $2,607,000.00 |
| Revenue This Year | $9.71 | $35.64 |
| Revenue Next Year | $7.82 | $34.12 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.25 | $3.50 |
| 52 Week High | $24.64 | $8.40 |
| Indicator | SGRY | ARDX |
|---|---|---|
| Relative Strength Index (RSI) | 40.91 | 48.23 |
| Support Level | $13.14 | $5.49 |
| Resistance Level | $16.28 | $8.23 |
| Average True Range (ATR) | 0.73 | 0.37 |
| MACD | -0.07 | -0.03 |
| Stochastic Oscillator | 49.87 | 61.02 |
Surgery Partners Inc is a healthcare services company with an integrated outpatient delivery model focused on providing quality, cost-effective solutions for surgical and related ancillary care in support of both patients and physicians. It has one reportable segment: Surgical Facilities which includes the operation of ASCs, surgical hospitals, anesthesia services, and multi-specialty physician practices, which earns revenues from contracts with patients in which the performance obligations are to provide health care services.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.